Overcoming tumor antigen heterogeneity in CAR-T cell therapy for malignant mesothelioma (MM)

Abstract

Malignant mesothelioma (MM) is a rare, aggressive solid tumor with limited therapeutic options and poor therapeutic response. The role of immunotherapy in MM is now well established and therapeutic options, such as checkpoint inhibitors, are increasingly being approved. Chimeric antigen receptor (CAR)-T cell therapy is successfully implemented in several hematologic cancers, but currently has inadequate effect in solid tumors, owing to several limitations, such as trafficking and infiltration, limited T cell persistence and exhaustion, the immunosuppressive TME and tumor antigen heterogeneity. The lack of uniform and universal expression of tumor-associated antigens (TAAs) on tumor cells, as well as TAA heterogeneity following tumor editing post-therapy, are issues of significant importance to CAR-T cell and associated antigen-targeting therapies. Our review discusses the concept of tumor antigen heterogeneity in MM, the consequences for CAR-T cell therapies and the strategies to overcome it.

Keywords

Antigen heterogeneity / chimeric antigen receptor (CAR) T cells / mesothelioma / tumor-associated antigens (TAAs) / bystander effect / epitope spreading / tumor microenvironment

References

[1] Brims F.Epidemiology and clinical aspects of malignant pleural mesothelioma.Cancers (Basel)2021;13:4194 PMCID:PMC8391310

[2] Ziółkowska B,Papantoniou D.Systemic treatment in patients with malignant pleural mesothelioma - real life experience.BMC Cancer2022;22:432 PMCID:PMC9022247

[3] Espinoza-Mercado F,Berz D.Disparities in compliance with national guidelines for the treatment of malignant pleural mesothelioma.Ann Thorac Surg2019;108:889-96

[4] Baas P,Nowak AK.First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.Lancet2021;397:375-86

[5] Broeckx G.Malignant peritoneal mesothelioma: a review.Transl Lung Cancer Res2018;7:537-42 PMCID:PMC6204422

[6] Vogelzang NJ,Symanowski J.Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.J Clin Oncol2003;21:2636-44

[7] Kindler HL,Armato SG.Treatment of malignant pleural mesothelioma: American society of clinical oncology clinical practice guideline.J Clin Oncol2018;36:1343-73

[8] Zalcman G,Margery J.Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.Lancet2016;387:1405-14

[9] Neumann V,Müller KM.Malignant mesothelioma - German mesothelioma register 1987-1999.Int Arch Occup Environ Health2001;74:383-95

[10] Tracey EKT,Currow D. Cancer in NSW: incidence and mortality report 2008. Sydney: Cancer Institute NSW, 2010.

[11] Tano ZE,Li X.Novel immunotherapy clinical trials in malignant pleural mesothelioma.Ann Transl Med2017;5:245 PMCID:PMC5497103

[12] Rijavec E,Barletta G,Genova C.Novel approaches for the treatment of unresectable malignant pleural mesothelioma: a focus on immunotherapy and target therapy (Review).Mol Clin Oncol2022;16:89 PMCID:PMC8892433

[13] Chen N,Chintala NK,Adusumilli PS.Driving CARs on the uneven road of antigen heterogeneity in solid tumors.Curr Opin Immunol2018;51:103-10 PMCID:PMC5943172

[14] Albelda SM.Tumor antigen heterogeneity: the “Elephant in the Room” of adoptive T-cell therapy for solid tumors.Cancer Immunol Res2020;8:2

[15] Garland LL,Gandara DR.Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.J Clin Oncol2007;25:2406-13

[16] Govindan R,Herndon JE.Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.Clin Cancer Res2005;11:2300-4

[17] Ou WB,Corson JM.Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.Neoplasia2011;13:12-22 PMCID:PMC3022424

[18] Ou SH,Garland LL.SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).J Thorac Oncol2015;10:387-91 PMCID:PMC4304604

[19] Avelumab in metastatic or locally advanced solid tumors (JAVELIN solid tumor). Available from: https://ClinicalTrials.gov/show/NCT01772004 [Last accessed on 21 July 2022].

[20] Gounant V,Zalcman G.Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment.Ther Adv Med Oncol2021;13:17588359211061956 PMCID:PMC8669877

[21] Brockwell NK,Kumar B,John T.Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma.Transl Lung Cancer Res2020;9:639-45 PMCID:PMC7354134

[22] Zalcman G,Greillier L.Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD).Ann Oncol2019;30:v747

[23] Pagano M,Zucali PA.Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study.JCO2020;38:9004

[24] Toyokawa G,Hirai F.Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.Int J Clin Oncol2014;19:601-6

[25] Tourkantonis I,Ralli M.Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.Am J Clin Oncol2011;34:38-42.

[26] Kim RY,Marmarelis ME.Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.Lung Cancer2021;159:107-10 PMCID:PMC8411329

[27] Popat S,Dafni U.A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.Ann Oncol2020;31:1734-45

[28] Yarchoan M,Hopkins AC.PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.JCI Insight2019;4:126908 PMCID:PMC6482991

[29] Raghav K,Overman MJ.Efficacy, safety, and biomarker analysis of combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) blockade in advanced malignant peritoneal mesothelioma.Cancer Discov2021;11:2738-47 PMCID:PMC8563380

[30] Fournier C,Zitvogel L,Galluzzi L.Trial watch: adoptively transferred cells for anticancer immunotherapy.Oncoimmunology2017;6:e1363139 PMCID:PMC5674950

[31] Garber K.Driving T-cell immunotherapy to solid tumors.Nat Biotechnol2018;36:215-9

[32] Sadelain M,Rivière I.The basic principles of chimeric antigen receptor design.Cancer Discov2013;3:388-98 PMCID:PMC3667586

[33] Thistlethwaite FC,Guest RD.The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.Cancer Immunol Immunother2017;66:1425-36 PMCID:PMC5645435

[34] Zhong XS,Plotkin J,Sadelain M.Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.Mol Ther2010;18:413-20 PMCID:PMC2839303

[35] Chang K,Batra JK,Willingham MC.Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium.Cancer Res1992;52:181-6

[36] Pastan I.Discovery of mesothelin and exploiting it as a target for immunotherapy.Cancer Res2014;74:2907-12 PMCID:PMC4062095

[37] Morello A,Adusumilli PS.Mesothelin-targeted CARs: driving T cells to solid tumors.Cancer Discov2016;6:133-46 PMCID:PMC4744527

[38] Bera TK.Mesothelin is not required for normal mouse development or reproduction.Mol Cell Biol2000;20:2902-6

[39] Castelletti L,van Zandwijk N.Anti-mesothelin CAR T cell therapy for malignant mesothelioma.Biomark Res2021;9:11

[40] Klampatsa A,Albelda SM.Mesothelin-targeted CAR-T cell therapy for solid tumors.Expert Opin Biol Ther2021;21:473-86

[41] Klampatsa A,Davies DM.Intracavitary “T4 immunotherapy” of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.Cancer Lett2017;393:52-9

[42] Al-Taei S,Lester JF.Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.Lung Cancer2012;77:312-8

[43] Klampatsa A,Moon EK.Chimeric antigen receptor (CAR) T cell therapy for malignant pleural mesothelioma (MPM).Cancers (Basel)2017;9:115 PMCID:PMC5615330

[44] Thayaparan T,Achkova DY.CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.Oncoimmunology2017;6:e1363137 PMCID:PMC5706532

[45] Hyrenius-Wittsten A,Park M.SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models.Sci Transl Med2021;13:eabd8836 PMCID:PMC8594452

[46] Bughda R,D’Souza RR.Fibroblast activation protein (FAP)-targeted CAR-T cells: launching an attack on tumor stroma.Immunotargets Ther2021;10:313-23 PMCID:PMC8354246

[47] Petrausch U,Hagedorn C.Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).BMC Cancer2012;12:615 PMCID:PMC3585825

[48] Schuberth PC,Jensen SM.Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.J Transl Med2013;11:187 PMCID:PMC3751305

[49] Hiltbrunner S,Schuberth P.Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial.Ann Oncol2021;32:120-1

[50] Blum Y,Quetel L.Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.Nat Commun2019;10:1333 PMCID:PMC6430832

[51] Yoshikawa Y,Tsujimura T.Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma.Cancer Sci2012;103:868-74 PMCID:PMC7659203

[52] Kiyotani K,Inoue H.Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma.Oncoimmunology2017;6:e1278330 PMCID:PMC5353938

[53] Junttila MR.Influence of tumour micro-environment heterogeneity on therapeutic response.Nature2013;501:346-54

[54] Oehl K,Opitz I.Heterogeneity in malignant pleural mesothelioma.Int J Mol Sci2018;19:1603 PMCID:PMC6032160

[55] Lee HS,Choi JM.Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.JCI Insight2018;3:98575 PMCID:PMC5928857

[56] Chen R,Fujimoto J.Evolution of genomic and T-cell repertoire heterogeneity of malignant pleural mesothelioma under dasatinib treatment.Clin Cancer Res2020;26:5477-86 PMCID:PMC7709879

[57] Sneddon S,Ma S.Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma.Oncoimmunology2020;9:1684713 PMCID:PMC6959430

[58] Mansfield AS,Smadbeck JB.Neoantigenic potential of complex chromosomal rearrangements in mesothelioma.J Thorac Oncol2019;14:276-87 PMCID:PMC6348045

[59] Majzner RG.Tumor antigen escape from CAR T-cell therapy.Cancer Discov2018;8:1219-26

[60] Rafiq S,Brentjens RJ.Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nat Rev Clin Oncol2020;17:147-67 PMCID:PMC7223338

[61] Minnema-Luiting J,Aerts J.Heterogeneity in immune cell content in malignant pleural mesothelioma.Int J Mol Sci2018;19:1041 PMCID:PMC5979422

[62] Newick K,Moon E.CAR T cell therapy for solid tumors.Annu Rev Med2017;68:139-52

[63] Wei J,Bo J.Target selection for CAR-T therapy.J Hematol Oncol2019;12:62 PMCID:PMC6587237

[64] Valitutti S,Cella M,Lanzavecchia A.Serial triggering of many T-cell receptors by a few peptide-MHC complexes.Nature1995;375:148-51

[65] Alvarez-Vallina L.Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies.Hum Gene Ther1999;10:559-63

[66] Watanabe K,Martens AC.Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.J Immunol2015;194:911-20

[67] Chmielewski M,Abken H.CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.Gene Ther2011;18:62-72

[68] Frigault MJ,Basil MC.Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.Cancer Immunol Res2015;3:356-67 PMCID:PMC4390458

[69] Viganò S,Perreau M,Zehn D.Functional avidity: a measure to predict the efficacy of effector T cells?.Clin Dev Immunol2012;2012:153863 PMCID:PMC3511839

[70] Zeh HJ,Dudley ME,Yang JC.High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.J Immunol1999;162:989-94

[71] Walker AJ,Zhang L.Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase.Mol Ther2017;25:2189-201 PMCID:PMC5589087

[72] Arcangeli S,Bardelli M.Balance of Anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia.Mol Ther2017;25:1933-45 PMCID:PMC5542631

[73] Morgan RA,Kitano M,Laurencot CM.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.Mol Ther2010;18:843-51 PMCID:PMC2862534

[74] Liu X,Fang C.Affinity-Tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice.Cancer Res2015;75:3596-607 PMCID:PMC4560113

[75] Drent E,Poels R.A rational strategy for reducing On-Target Off-Tumor effects of CD38-chimeric antigen receptors by affinity optimization.Mol Ther2017;25:1946-58 PMCID:PMC5542711

[76] O’Rourke DM,Desai A.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Sci Transl Med2017;9:eaaa0984 PMCID:PMC5762203

[77] Rafiq S.Tumors evading CARs-the chase is on.Nat Med2018;24:1492-3

[78] Larson RC,Bailey SR.CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.Nature2022;604:563-70

[79] Hegde M,Grada Z.Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.J Clin Invest2016;126:3036-52

[80] Dao T,Scott A.Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.Nat Biotechnol2015;33:1079-86 PMCID:PMC4600043

[81] Adusumilli PS,Rivière I.A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 agent pembrolizumab.Cancer Discov2021;11:2748-63 PMCID:PMC8563385

[82] Brossart P.The Role of antigen spreading in the efficacy of immunotherapies.Clin Cancer Res2020;26:4442-7

[83] Beatty GL,Maus MV.Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.Cancer Immunol Res2014;2:112-20 PMCID:PMC3932715

[84] Klampatsa A,Sun J,Arguiri E.Analysis and augmentation of the immunologic bystander effects of car T cell therapy in a syngeneic mouse cancer model.Mol Ther Oncolytics2020;18:360-71 PMCID:PMC7417672

[85] Choe JH,Simic MS.SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma.Sci Transl Med2021;13:eabe7378 PMCID:PMC8362330

[86] Anurathapan U,Hindi HF.Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.Mol Ther2014;22:623-33 PMCID:PMC3945803

[87] Song DG,Poussin M,Figini M.Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.J Hematol Oncol2016;9:56 PMCID:PMC4955216

[88] Smith TT,Stephan SB.Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.J Clin Invest2017;127:2176-91 PMCID:PMC5451231

[89] Chen SH,Wang P,Konstantopoulos K.Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.Sci Rep2013;3:1870 PMCID:PMC3660778

[90] Zhang L,Muranski P.Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.Gene Ther2013;20:575-80 PMCID:PMC6348484

[91] Cherkassky L,Villena-Vargas J.Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.J Clin Invest2016;126:3130-44 PMCID:PMC4966328

[92] Fedorov VD,Sadelain M.PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.Sci Transl Med2013;5:215ra172 PMCID:PMC4238416

[93] Rodgers DT,Hampton EN.Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.Proc Natl Acad Sci USA2016;113:E459-68 PMCID:PMC4743815

[94] Choi BD,Castano AP.CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.Nat Biotechnol2019;37:1049-58

[95] Chintala NK,Quach H.CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.Lung Cancer2021;157:48-59 PMCID:PMC8184643

[96] Sánchez-Paulete AR,Cueto FJ.Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.Ann Oncol2017;28:xii44-55

[97] Gulley JL,Pachynski R.Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment.J Natl Cancer Inst2017;109 PMCID:PMC5441294

[98] Kim RH,Gladney W.Effect of chimeric antigen receptor (CAR) T cells on clonal expansion of endogenous non-CAR T cells in patients (pts) with advanced solid cancer.JCO2017;35:3011-3011

[99] Lai J,House IG.Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.Nat Immunol2020;21:914-26

[100] Xin G,Topchyan P.Pathogen-boosted adoptive cell transfer therapy induces endogenous antitumor immunity through antigen spreading.Cancer Immunol Res2020;8:7-18 PMCID:PMC6946848